Wharton’s Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study

Table 4

Efficacy of treatment in subgroups identified on the basis of minimal cell dose per administration.

Minimal dose (×10^6//kg)	N	Average QoL response per one administration; ( = not significant)					Developmental breakthrough; ( = not significant)						Proportion of patients with developmental breakthrough
		<1				≥4	0	1	2	3	4	5
≤0.77 (≤Q1)	14	6	5	2	1	0	8	4	1	0	1	0	7.1%
>0.77-≤0.91 (Q1-Q2)	16	7	2	4	3	0	0	0	0	3	2	0	31.25%
>0.91-≤1.0 (Q2-Q3)	12	6	4	1	0	1	9	1	1	1	0	0	8.3%
>1.0 (>Q3)	12	4	3	5	0	0	5	0	1	3	3	0	50%

QoL: quality of life; Q: quartile. The highest improvement in quality of life between two consecutive assessments. Cells marked in bold represent categorization used in Yates’ chi-square test.